Sugi Predict

Sugi Predict / Compounds / SCHEMBL30364495

SCHEMBL30364495

SCHEMBL30364495

CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)CN)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H](C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(N)=O)[C@@H](C)CC)C(C)C)C(C)C)C(C)C)C(C)C

nearest known ligand 0.68

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ TFPI P10646 6/20 0.68
▸ NPY2R P49146 7/20 0.62
▸ NPY4R P50391 7/20 0.62
▸ NPY5R Q15761 7/20 0.62
▸ NPY1R P25929 5/20 0.62
▸ CXCR4 P61073 1/20 0.61
▸ REN P00797 3/20 0.60
▸ RAMP3 O60896 1/20 0.59
▸ CALCR P30988 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29614957 0.97 TFPI (0.63) TFPINPY2RNPY4RNPY5RNPY1R
SCHEMBL31418387 0.95 TFPI (0.63) TFPINPY2RNPY4RNPY5RNPY1R
SCHEMBL30872190 0.93 CXCR4 (0.64) TFPINPY2RNPY4RNPY5RNPY1R
Melectin SCHEMBL30448502 0.90 REN (0.62) TFPIREN
SCHEMBL29358935 0.87 TFPI (0.64) TFPINPY2RNPY4RNPY5RNPY1R
SCHEMBL30300729 0.85 REN (0.63) NPY2RNPY4RNPY5RNPY1RREN
SCHEMBL29615082 0.85 CALCR (0.61) NPY2RNPY4RNPY5RNPY1RRAMP3
SCHEMBL29614997 0.85 GLP1R (0.62) NPY2RNPY4RNPY5RNPY1RCALCR
SCHEMBL29416782 0.85 CALCR (0.62) NPY2RNPY4RNPY5RNPY1RRAMP3
SCHEMBL30711673 0.84 PTH1R (0.68) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250288656-A1 APPLICATION OF CAERIN 1.1/1.9 COMBINED WITH ANTI-CD47 ANTIBODY IN PREPARING DRUG FOR TREATING MELANOMA WNL BIOMED TECH PTY. LTD. (AU) 2025-09-18 — — US claimed
US-12377186-B2 Antimicrobial biopolymer compositions, methods of synthesis, and applications of use ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2025-08-05 — — US claimed
CN-118290531-A Iodine-131 marked small molecule polypeptide TFMP-Y2 and preparation method and application thereof 广州港湾医疗器械有限公司 2024-07-05 — — CN claimed
WO-2024109339-A1 USE OF CAERIN1.1/1.9 COMBINED WITH ANTI-CD47 ANTIBODY IN PREPARATION OF DRUG FOR TREATMENT OF MELANOMA 中奥生物医药技术(广东)有限公司 2024-05-30 — — WO claimed
CN-115969960-A Application of Caerin1.1/1.9 peptide in preparation of drugs for inhibiting/treating bacterial biofilm growth 中奥生物医药技术(广东)有限公司 2023-04-18 — — CN claimed
CN-115957306-A Application of Caerin1.1/1.9 combined anti-CD47 antibody in preparation of drugs for treating melanoma 中奥生物医药技术(广东)有限公司 2023-04-14 — — CN claimed
CN-121910847-A Use of caerin 1.1.1/1.9 and polymyxin B composition in preparation of anti-Acinetobacter baumannii medicine 中奥生物医药技术(广东)有限公司 2026-04-24 — — CN disclosed
CN-121910847-A Use of caerin 1.1.1/1.9 and polymyxin B composition in preparation of anti-Acinetobacter baumannii medicine 中奥生物医药技术(广东)有限公司 2026-04-24 — — CN disclosed
CN-121796558-A Caerin 1.1.1/1.9 application in preparing antiviral drug 中奥生物医药技术(广东)有限公司 2026-04-07 — — CN disclosed
CN-121796558-A Caerin 1.1.1/1.9 application in preparing antiviral drug 中奥生物医药技术(广东)有限公司 2026-04-07 — — CN disclosed
WO-2025209211-A1 IODINE-131-LABELED SMALL-MOLECULE POLYPEPTIDE TFMP-Y2, AND PREPARATION METHOD THEREFOR AND USE THEREOF 广州港湾医疗器械有限公司 2025-10-09 — — WO disclosed
EP-4626453-A1 PEPTIDE WITH ANTI-INFLAMMATORY AND ANTI-MICROBIAL ACTIVITY Isanaka, Ramakrishna Reddy (IN) 2025-10-08 — — EP disclosed
US-20250288656-A1 APPLICATION OF CAERIN 1.1/1.9 COMBINED WITH ANTI-CD47 ANTIBODY IN PREPARING DRUG FOR TREATING MELANOMA WNL BIOMED TECH PTY. LTD. (AU) 2025-09-18 — — US disclosed
WO-2024104197-A1 PEPTIDE HYDROGEL, PREPARATION METHOD THEREFOR AND USE THEREOF IN TREATMENT 中国科学院过程工程研究所 2024-05-23 — — WO disclosed
CN-117982626-A Application of F1/F3 polypeptide in preparation of medicines for inducing tumor cell apoptosis 中奥生物医药技术(广东)有限公司 2024-05-07 — — CN disclosed
CN-115957306-B Application of Caninin 1.1/1.9 combined anti-CD47 antibody in preparation of medicine for treating melanoma 中奥生物医药技术(广东)有限公司 2023-08-22 — — CN disclosed
CN-115957306-B Application of Caninin 1.1/1.9 combined anti-CD47 antibody in preparation of medicine for treating melanoma 中奥生物医药技术(广东)有限公司 2023-08-22 — — CN disclosed
CN-115969960-A Application of Caerin1.1/1.9 peptide in preparation of drugs for inhibiting/treating bacterial biofilm growth 中奥生物医药技术(广东)有限公司 2023-04-18 — — CN disclosed
CN-115957306-A Application of Caerin1.1/1.9 combined anti-CD47 antibody in preparation of drugs for treating melanoma 中奥生物医药技术(广东)有限公司 2023-04-14 — — CN disclosed
CN-115957306-A Application of Caerin1.1/1.9 combined anti-CD47 antibody in preparation of drugs for treating melanoma 中奥生物医药技术(广东)有限公司 2023-04-14 — — CN disclosed
Send feedback